Most obesity drugs do not improve quality of life or heart health, analysis indicates. Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, and few show cardiovascular benefits at one year, according to an analysis of the latest evidence published by The BMJ.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, and few show cardiovascular benefits at one year, according to an analysis of the latest evidence published by The BMJ.
- Ponto de atenção: most.
- Ponto de atenção: obesity.
- Ponto de atenção: drugs.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
